IMRX
Price
$3.59
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
124.15M
31 days until earnings call
NUVL
Price
$80.48
Change
-$0.02 (-0.02%)
Updated
Jul 3 closing price
Capitalization
5.78B
32 days until earnings call
Interact to see
Advertisement

IMRX vs NUVL

Header iconIMRX vs NUVL Comparison
Open Charts IMRX vs NUVLBanner chart's image
Immuneering
Price$3.59
Change-$0.00 (-0.00%)
Volume$25.3K
Capitalization124.15M
Nuvalent
Price$80.48
Change-$0.02 (-0.02%)
Volume$299.2K
Capitalization5.78B
IMRX vs NUVL Comparison Chart in %
Loading...
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMRX vs. NUVL commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRX is a Hold and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (IMRX: $3.45 vs. NUVL: $80.48)
Brand notoriety: IMRX and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMRX: 64% vs. NUVL: 53%
Market capitalization -- IMRX: $124.15M vs. NUVL: $5.78B
IMRX [@Biotechnology] is valued at $124.15M. NUVL’s [@Biotechnology] market capitalization is $5.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMRX’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • IMRX’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than IMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMRX’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 5 bullish TA indicator(s).

  • IMRX’s TA Score: 4 bullish, 4 bearish.
  • NUVL’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than IMRX.

Price Growth

IMRX (@Biotechnology) experienced а +8.15% price change this week, while NUVL (@Biotechnology) price change was +1.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

IMRX is expected to report earnings on Nov 06, 2025.

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.78B) has a higher market cap than IMRX($124M). IMRX YTD gains are higher at: 56.818 vs. NUVL (2.810). IMRX has higher annual earnings (EBITDA): -63.85M vs. NUVL (-322.59M). NUVL has more cash in the bank: 1.07B vs. IMRX (35.9M). IMRX (0) and NUVL (0) have equivalent revenues.
IMRXNUVLIMRX / NUVL
Capitalization124M5.78B2%
EBITDA-63.85M-322.59M20%
Gain YTD56.8182.8102,022%
P/E RatioN/AN/A-
Revenue00-
Total Cash35.9M1.07B3%
Total Debt4.08MN/A-
TECHNICAL ANALYSIS
Technical Analysis
IMRXNUVL
RSI
ODDS (%)
Bearish Trend 4 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 17 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
78%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OTTW15.250.10
+0.66%
Ottawa Bancorp, Inc.
LNNGF2.00N/A
N/A
Li Ning Co., Ltd.
LOQPF6.76N/A
N/A
Accesso Technology Group Plc
NCHEY12.10N/A
N/A
Nichirei Corp
CTGSP2.93N/A
N/A
Connecticut Natural Gas Corp.

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with CGON. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-0.02%
CGON - NUVL
55%
Loosely correlated
+2.09%
ABCZF - NUVL
51%
Loosely correlated
N/A
CRNX - NUVL
51%
Loosely correlated
+1.22%
KYMR - NUVL
50%
Loosely correlated
+0.58%
RARE - NUVL
49%
Loosely correlated
+1.14%
More